Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

345
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
345
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

801
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
801
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

314
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
314
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

311
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
311
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

330
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
330
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

319
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
319

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune Profiling Identifies Inflammatory Signatures in Immune Checkpoint Inhibitor-Related Myocarditis.

JACC. CardioOncology·2026
Same author

[Oncology : what's new in 2025].

Revue medicale suisse·2026
Same author

Implant Therapy in Patients With Neurodegenerative Diseases-A Scoping Review.

Clinical oral implants research·2026
Same author

[How Do Older People Perceive Deprescribing? A systematic integrative literature review].

Praxis·2025
Same author

Detection of spontaneous anti-neoepitope T-cell responses in non-metastatic bladder cancer patients.

Frontiers in immunology·2025
Same author

[Prescribed autonomy : outpatient comprehensive geriatric assessment].

Revue medicale suisse·2025
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026
See all related articles

Related Experiment Video

Updated: Mar 24, 2026

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty
07:27

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty

Published on: October 6, 2016

11.0K

[Geriatry].

Pierre-olivier Lang, Sylvain Nguyen, Nabila Ferahta

    Revue Medicale Suisse
    |March 8, 2016
    PubMed
    Summary
    This summary is machine-generated.

    Treatment goals for hypertension and TAVI should be individualized for elderly patients. New vaccines show promise against pneumonia and shingles, while dementia prevention and Alzheimer's monitoring advance.

    More Related Videos

    Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
    12:59

    Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

    Published on: July 5, 2017

    13.3K
    Frailty Assessment in an Aging Mouse Model
    06:58

    Frailty Assessment in an Aging Mouse Model

    Published on: September 23, 2025

    832

    Related Experiment Videos

    Last Updated: Mar 24, 2026

    Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty
    07:27

    Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty

    Published on: October 6, 2016

    11.0K
    Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
    12:59

    Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

    Published on: July 5, 2017

    13.3K
    Frailty Assessment in an Aging Mouse Model
    06:58

    Frailty Assessment in an Aging Mouse Model

    Published on: September 23, 2025

    832

    Area of Science:

    • Cardiology
    • Infectious Diseases
    • Neurology
    • Endocrinology

    Context:

    • 2015 research highlights individualized treatment for hypertension and TAVI in vulnerable populations.
    • Advances in vaccines target community-acquired pneumonia and shingles.
    • Testosterone supplementation's role in arteriosclerotic disease is clarified.
    • Dementia risk reduction and Alzheimer's disease monitoring are key research areas.

    Purpose:

    • To summarize key medical research findings from 2015 across various disciplines.
    • To highlight advancements in preventative medicine and disease management.
    • To underscore the importance of personalized medicine and emerging therapeutic strategies.

    Summary:

    • Individualized treatment is crucial for hypertension and TAVI in the elderly.
    • New vaccines offer improved protection against pneumonia and shingles.
    • Testosterone supplementation is ineffective for arteriosclerotic disease.
    • Multimodal approaches can reduce cognitive decline risk.
    • Tau-tracer imaging aids Alzheimer's monitoring; anti-amyloid vaccines show promise.

    Impact:

    • Informs clinical practice regarding patient-specific care for hypertension and TAVI.
    • Expands options for infectious disease prevention.
    • Clarifies therapeutic guidelines for arteriosclerotic conditions.
    • Provides evidence for dementia risk reduction strategies.
    • Advances diagnostic and therapeutic avenues for Alzheimer's disease.